Clinical Conversations®: Achieving Success in RA Assessment and Management

Program Overview

This activity features 2 patient cases, challenging interactive questions related to the cases, and video vignettes. You will have an opportunity to hear from our expert faculty and view practical examples of shared decision making.
Launch Date: February 27, 2018

Credit Expired
CE Credit Expired

Target Audience

Rheumatologists – Relevant Terms: Rheumatoid Arthritis

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach
  • Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA
  • Develop individualized treatment plans for patients with RA that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDS) based on safety and efficacy data
  • Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  • Integrate shared decision making and other patient education strategies for patients with RA

Activity Faculty

Martin Jan Bergman, MD, FACR, FACP, FCPP

Martin Jan Bergman, MD, FACR, FACP, FCPP

Clinical Associate Professor, Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA

Sergio Schwartzman, MD

Sergio Schwartzman, MD

Franchellie M. Cadwell Associate Professor, Clinical Medicine
Weill Cornell Medical College
Associate Attending Physician
New York Presbyterian Hospital
Hospital for Special Surgery
New York, NY

Supporter Statement

Provider Statement

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources